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Macrophage antibody-dependent cellular cytotoxicity (ADCC) to tumor targets
is subject to in vivo and in vitro regulation (reviewed in reference 1). Among
endogenous macrophage-stimulating factors, y interferon (IFN-y) is well known
for inducing nonspecific tumoricidal activity (e.g., reference 2). Using individual
purified factors and neutralizing antibodies, we show here that murine IFN-a,
IFN-,Q, rIFN-y, and rIL-2, but not rIL-4, stimulate ADCC.
Materials and Methods
Effector Cells. Adherent peritoneal exudate macrophages from protease peptone-
injected C3H/HeN mice (Charles River Breeding Laboratories, Inc., Kingston, NY) were
prepared as described (3). The adherent cells were >95% macrophages (3). The cells
were incubated for 2 d in medium ± factors (1); the cell number did not change during
this time.
Lymphokines.
￿
Mitogen-induced lymphokine was the supernatant of 2 x 106/ml normal
mouse spleen cells cultured 2 d with 10 jug/ml Con A (Sigma Chemical Co., St. Louis,
MO). Mock lymphokine supernatant collected 1 h after addition of Con A to cells did not
stimulate ADCC. Murine rIFN-y (a gift from Schering-Plough Corp., Kenilworth, NJ),
purified rIL-4 (4), IFN-a (Lee BioMolecular, San Diego, CA), IFN-S (Lee BioMolecular),
and human rIL-2 (Cetus Corp., Emeryville, CA) were used as stimulators. Rabbit anti-
human IL-2 raised to humanrIL-2 produced in Escherichia coli (neutralizing titer of 3,100
n.u./ml, M. V . Doyle, Cetus Corp.), R4-6A2 monoclonal anti-mouse IFN-y (Lee Bio-
Molecular), and 11 BI 1 monoclonal anti-IL-4 (5) were used. 11 B 11 antibody was produced
from the hybridoma cells serum free, purified by ammonium sulfate precipitation and
protein A-agarose chromatography, coupled to Affi-Gel 10 (Bio-Rad Laboratories, Rich-
mond, CA), and used as an immunoaffinity column to deplete Con A lymphokine of
IL-4 activity. IFN was assayed by vesicular stomatitis virus infection of L929 and IL-2 by
proliferation ofHT-2 cells ± anti-IL-4. IL-4 in lymphokine was determined by T. Mossman
(DNAX, LaJolla, CA) using the HT-2 proliferation assay ± anti-IL-4 and anti-IL-2 .
Cytotozicity Assays.
￿
ADCC was measured by adding 2 x 10' mouse thymoma RI cells
to effector cells at an E/T ratio of 1 :1 to 6:1. Rabbit anti-mouse brain (anti-Thy-1)
(Accurate Chemical & Scientific Corp., Westbury, NY) was used at 1 :2,000 in the assay,
except as noted. Controls lacking antibody, or macrophages, or both, were run in replicate
in all experiments (3). ADCC was determined at 9 or 24 h by vigorously pipetting
nonadherent cells and performing a viable count in a hemacytometer. Results are stated
as means ± SEM. Cultures containing factors ± antiserum but lacking macrophages did
not differ from R1 only cultures by >10% on average. Percent ADCC is calculated as
(1 - A/C) x 100, where A and C are target cell counts from wells with similarly treated
macrophages with and without antiserum, respectively. Percent ADCC induced by the
2-d pretreatment is calculated as 100 x [(X - Y)/(100 - Y)], where X and Y are percent
ADCC values for factor-stimulated and medium control macrophages, respectively.
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Stimulation ofMacrophage ADCC by rIFN--y, IL-2, IFN-a, and IFN-(3
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Macrophages were tested 2 d with medium, ConA-induced lymphokine (LK), or factors, and then
assayed forkillingR1 targets at an E/Tratio of 6. Targets were not affected by antiserum or LKs
in theabsence of macrophages.
* Viable targets (X10'/ml)at 9 and 24 h.
ADCC inducedby agent pretreatment was determined by comparison with mediacontrol.
§Significantly different from medium control, p < 0.05.
Results
ADCC-stimulating Effect of Individual IFNs and IL-2.
￿
We previously showed
that a 2-d incubation of mouse peritoneal exudate macrophages in culture with
Con A-induced lymphokine was optimal for stimulating ADCC (1). We followed
this protocol to study the effect of individual factors. The RI thymoma cell line
was used as the target since it is very sensitive to macrophage ADCC, but fairly
resistant to nonspecific killing and NK lysis (3). The assay used visual counting
of target cells surviving macrophage coculture at 9 and 24 h. The R1 targets are
easily distinguished from peritoneal cells by size. A single batch of Con A-
induced lymphokine was used throughout these experiments, and it contained
35 U/ml of IFN activity, 92 U/ml IL-2, and 58 U/ml IL-4, and <0.2 ng/ml
LPS. Table I shows that recombinant murine IFN-y greatly potentiates ADCC
at 5 and 50 U/ml, with moderate effects seen at 1 U/ml. Comparison of the
titration of Con A-induced lymphokine and IFN-y in three experiments (Table
I and not shown) suggests that 5% lymphokine has the activity of ^r2-4 U/ml
IFN-y in this assay. Rat rIFN-y (Amgen, Thousand Oaks, CA) had almost the
identical effect as mouse IFN-y on murine macrophage ADCC.
IFN-ca and IFN-,Q also stimulate ADCC, but at higher concentrations than for
IFN-y (Table I). In three experiments with each type, 50 U/ml IFN-a or IFN-,Q
had about the same potentiating activity as 5 U/ml IFN-y. Human rIL2 also
Exp.
Pre-
treat-
ment
U/ml
-As*
9h
+As* %
ADCC
%
A* -As*
24h
+As*
ADCC At
1 Medium 19* 1 12 1 0 39 ± 6 43 ± 1 29 ± 1 33 ± 3
IFN-y 50 21 ± 0.5 1 ± 1 95 ± 5 92§ 41 ± 1.5 4 ± 1.5 90 ± 6 856
5 21±0 212 86±9 77§ 4712.5 5±0 89±7 849
1 21±1 9±1 5717 30 44±1 .5 23±2 48±6 22
LK20% 18±0 2±0 91±0 85§ 401.5 3±0 92±5 88§
5% 20 ± 0.5 3 ± 1 85 1 8 75§ 43 1 1 7 ± 0.5 84 ± 3 76§
1% 20±0.5 9±1.5 558 26 42±1 .5 21±1 50±4 25
IL-2 50 20 ± 2 6 ± 1 70 50 41 ± 0 5 ± 0 88 82§
5 22±1 8±0.5 64 40 43±1 .5 8±0.5 81 72§
1 20 ± 0 10 ± 0.5 50 18 45 ± 1 23 ± 1 49 24
2 Medium 14 ± 0.5 14 ± 1.5 0 45 ± 2 47 ± 5 0
IFN-a 50 15 ± 1.5 8 ± 1 47 47§ 44 ± 0 22 ± 1 50 50§
10 14±0 11±2 21 21 45±2 32±2 29 29
5 13±0 12±1 .5 9 9 48±3 47±2 2 2
1 16±1 .5 I6±1 0 0 45±1 49±2 0 0
IFN-# 50 13 ± 1 8 ± 0 39 469 42 ± 1 20 ± 1 52 52§
5 14±0.5 15±0.5 0 0 47±2 45±2 6 6
1 15±0.5 14±0.5 7 7 49±1 46±3 6 6
IFN-y 5 12 ± 1 7 ± 0.5 42 42§ 45 ± 01 24 ± 1 47 47§714
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TABLE II
Role ofIL-4 in Macrophage ADCC
Macrophages were pretreated with ILA, LK, or IL-4-depleted LK and assayed for ADCC as in Table 1. The LK contained 58
U/ml IL-4, and IL-4 in the depleted LK was undetectable (<5 U/ml). The results suggest that IL-4 does not stimulate ADCC.
* Viable targets surviving(X104/ml).
ADCC induced by pretreatmentsignificantly different from medium control.
TABLE III
Anti-IFN-7 Antibody Blocks the ADCC-stimulating Effect ofLK
Macrophages were pretreated with lymphokines ± neutralizing antibodies for 2 d andthen tested
for ADCC as in Table I. The anti-rIFN blocked the ADCC-stimulating activity of LK. The anti-
human IL-2 (50 n.u.) does not neutralize mouse IL-2; it blocked the ADCC-stimulating activity of
rhIL-2 but not that of the murine LK. The cultures containing the combination of LK, IL-2, and
anti-IFN--y show that the antibody did not nonspecifically block increased ADCC since a strong
augmentation was seen due to the IL-2 .
* Viable targets (X 104/ml) at 9 h.
$ Percent ADCC induced by pretreatment.
stimulated ADCC in the range of 5-50 U/ml (Table I) . When nonadherent cells
from the peritoneal exudate population were similarly incubated with IL-2, they
did not have any ADCC activity (not shown).
Effect of IL-4 and IL-4-depleted Lymphokine.
￿
Treatment of macrophages with
rIL4 did not stimulate ADCC, whereas Con A-induced lymphokine depleted of
IL-4 retained its activity (Table II). The results were seen, respectively, in three
and four separate experiments. This suggests that IL-4 does not play a major
role in this macrophage tumoricidal mechanism.
Anti-IFN-y Blocks Most of the Activity in Lymphokines.
￿
A neutralizing mAb was
used to assess the contribution of IFN-y to the activity in lymphokine. Table III
shows that 130 neutralizing units/ml of antibody almost completely blocked the
Exp. Pretreatment -As* +As* ADCC % Y
+ anti-IFN-,y (130
-As* +As*
n.u.)
%
ADCC
% A$
1 Media 16±0.5 12 t1 25 14±0 10±0.5 29 5
y-IFN 5 U/ml 14 ± 1 6 ± 2 57 43 15 ±0.5 12 ± 1 20 -7
LK20% 14±0.5 4±2 71 61 12±0 8±1.5 33 11
2 Media 23 ± 0.5 18 ± 1 22 22 ± 1 16 ± 2 27 6
LK 20% 22 ± 1.5 4 ± 0.5 82 77 20 ± 1 15 ± 0 25 4
IL-2 50 U/ml 25 ± 0.5 6 ± 1 75 68 21 ± 2 5 ± 0.5 76 69
IL-2 + a-IL-2 21 ± 0 15 ± 1 29 9
LK+1L-2 22±0 3±0 86 82 21±0.5 6±0 71 63
LK + a-IL-2 21 ± 1.5 5 ± 1 76 69
a-IL-2 26 ± 1 20 ± 1.5 23 1
Pretreatment U/ml
-As*
9h
+As*
ADCC % A -As*
24h
+As* ACC %
.1
Medium 23 1 0.5 18 ± 1 22 46 ± 3 38 ± 2 17
IL-4 100 25 t 1.5 20 t 0 20 -3 46 ± 0.5 36 ± 1 22 6
10 23 t0 17±2 26 5 42±2.5 32±2.5 24 8
1 24 t2 19±0.5 21 -1 44±1 3612.5 I8 I
LK 20% 22 t 1.5 4 t 0.5 82 771 43 ± 1 2 t 1 95 94$
5% 24 t1 9±1 62 51x 48±2.5 9±0.5 81 771
1% 22±0.5 13±0.5 41 24 48±0.5 30 t2 37 24
IL-4-depleted LK 20% 21 t 0.5 5 ± 0.5 76 70t 45 t 1.5 4 ± 0 91 89$
5% 22 1 0 9 1 0 59 471 44 ± 1 7 ± 0.5 84 81#
1% 22 1 1 12 ± 1 45 29 46 ± 1 30 ± 1.5 35 22RALPH ET AL .
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TABLE IV
Effect ofAntiserum Concentration and E/T Ratio on Stimulated ADCC
Macrophages were pretreated with medium or 1, 5, or 50 U/ml IFN-y for 2 d and assayed for ADCC at 5 :1 or 1 :1 ratio in the presence of
1 :2,000, 1:20,000, or 1 :200,000 dilution, or no antiserum.
* Viable targets (x 10'/m l) at 9 h .
Percent ADCC induced by pretreatment .
ADCC-stimulating activity of the Con A-induced lymphokine and of 5 or 50
U/ml IFN-y . It did not block the activity of IL-2 . One concern with adding a
neutralizing antibody into a reaction with macrophages is that nonspecific effects
due to Fc binding may occur . The ability of IL-2 to boostADCC in the presence
of Con A-induced lymphokine and neutralizing anti-IFN-y antibody suggests
that the antibody specifically abrogates the effect of IFN-y in the lymphokine .
Anti-human IL-2 blocked the activity of human rIL-2 . These results suggest
that IFN-y is the major factor in Con A-induced lymphokine which promotes
macrophage ADCC, although IL-2 must also be considered since its concentra-
tion in lymphokine may be high enough to have some effect .
Effect of Antiserum Concentration and E/T Ratio on Stimulated ADCC .
￿
The
previous experiments used a single E/T ratio and a relatively high antibody
concentration. The enhancement of killing by IFN-y is evident at 1:2,000
dilution of antiserum, which gives considerable spontaneous ADCC . Enhance-
ment is also seen at 10-fold and marginally at 100-fold lower amounts of
antiserum for which there is no spontaneous activity ; results typical of three
experiments are shown in Table IV . An E/T ratio of 5:1 allows enhanced
cytotoxicity of 70 to >90% of targets, but enhancement by IFN-y is seen even
at a ratio of 1 :1 (Table IV) .
Discussion
Our assay for ADCC, visual counts of surviving targets, is possible due to the
extreme sensitivity of the R 1 targets to this type of macrophage killing. The
results read at 24 h are very similar to the 9-h point, although the targets in the
nonmacrophage and no antibody controls frequently double in this time span.
This suggests that most of the killing occurs in the first 9 h and that the
subsequent growth of the survivors is similar to that of control tumor cells . We
defined "cytotoxicity" in terms offewertargets compared to controls ; tumorilysis
is only demonstrated when the number of surviving targets is less than the initial
number . This was the case with the higher concentrations of the active lympho-
kines studied .
IFN-y is well known as a stimulator of macrophage nonspecific tumoricidal
activity (2) . The results presented here demonstrate that IFN-y is also the major
factor in mitogen-induced lymphokine which stimulates macrophage ADCC,
E/T P
men[
t -As* 2,000* % ADCC % a$ 20,000* % ADCC % 200,000* % ADCC % 0$
5 Medium 31 ±:0 .5 17 ± 1 45 28 ± 2 10 34 ± 2 0
IFN-y 50 29 ± 1 2 ± 1 .5 93 87 8 ± 0 72 69 22 ± 2 24 24
5 25±0 3±0 .5 88 78 17±0 32 24 30±0 0 0
1 32±2 10±1 69 44 26±2 19 10 31±1 2 2
1 Medium 26 ± 2 21 ± 0 19 22 ± 1 15 24 ± 2 8
IFN-y 50 23 ± 1 10 ± 1 .5 57 47 1 1 ± 1 .5 52 44 21 ± 0 9 1
5 26±2 17±1 35 20 18±2 31 19 24±1 .5 8 0
1 24±2 .5 19±0 .5 21 2 19±0.5 21 7 n.d .716
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although IL-2, IFN-a, and IFN-0 have this activity as well. The effect is dose
dependent and is seen with a range of antibody concentrations. The IL-2-
stimulated ADCCappears to be a direct effect ofthelymphokine on macrophages
since nonadherent peritoneal cells did not manifest this activity. The possibility
that IL-2acted indirectly via thefewpercent oflymphoid cells in the macrophage
fraction was not investigated. Malkovsky et al. (6) reported that IL-2 also
stimulates human monocyte nonspecific tumoricidal activity.
IL-4 mediates multiple biological activities that affect various cell lineages.
With respect to macrophages, IL-4 has been shown to coregulate their CSF-
dependent growth, to increase la expression, and to augment their ability to
present antigen (reviewed in references 7 and 8). Crawford et al. (8) recently
showed that IL-4 stimulates peritoneal macrophages for increased nonspecific
cytotoxicity, but we found no effect of this LK in our ADCC system (Table II).
Crawford et al. (8) also showed that IL-4 increases the Fc receptor expression
(attributed to FcR type II) of bone marrow-derived macrophages. ADCC reac-
tions may differ in effector mechanisms and method of triggering, reviewed by
Johnson et al. (9). Therefore, our study ofADCC in one population ofperitoneal
macrophages, that elicited by proteose peptone, should be expanded to other
types ofcells and assays.
Other cytokines that interact with macrophages include IL-1, TNF, and CSF.
Macrophage-CSF induces nonspecific tumoricidal activity in murine macro-
phages andenhancesthatactivity inducedbycrude sources oflymphokine factors
(10) and by IFN--y (Ralph, P., and I. Nakoinz, manuscript in preparation). M-
CSF alone does not modulate macrophage ADCC, but it enhances the effect of
mitogen-induced lymphokine, and the IFNs and IL-2 (Ralph, P., and 1. Nakoinz,
manuscript in preparation). M-CSF is not detectable in mouse spleen lymphokine
(10). A preliminary investigation of IL-1 (Genzyme, Boston, MA) and human
rTNF (Cetus Corp.) showed no effect on ADCC at 1, 5, or 50 U/ml in our assay
(unpublished observations).
We showed previously that LPS could stimulate ADCC similarly to lympho-
kines, but only at high concentrations of 1 jAg/ml (1). The activity of mitogen-
induced lymphokine and individual factors studied here is notdue to LPS because
of their low content measured by the Limulus assay, because polymyxin B does
not abrogate the effect, and because LPS-hyporesponsive C3H/HeJ mice respond
to protein factors (Ralph, P., and 1. Nakoinz, manuscript in preparation).
This study used a polyclonal antiserum. All four murine IgGclasses arecapable
ofdirecting macrophage ADCC to tumor targets (3, 9), although the most active
mAbs tend to be of the IgG2a isotype (9). Immune lymphokine is reported to
increase macrophage expression of Fc receptors for IgG2a but not IgG2b (11).
The macrophage capacity for cytolysis must also be considered in the stimulation
ofADCC. In this respect, the difference between ADCC and "nonspecific" killing
oftumor targets isremarkable. With ADCC, maximum activity increases through
day 2 ofculture with LK while nonspecific killing is close to zero at this time (1,
10). In addition, the ADCC-sensitive R1 target is resistant to lymphokine-
induced, nonspecific killing. Further study is required to determine the contri-
butions of Fc receptors and "cytolytic capacity" of lymphokine-activated macro-
phages in ADCC.RALPH ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
717
Summary
Pretreatment ofmurine peritoneal exudate macrophages with 1-5 U/ml rIFN-
-y or rIL-2, or higher concentrations of IFN-a or IFN-(3 greatly stimulated ADCC
to Rl lymphoma targets. The assay was direct counting of viable target cells after
9 and 24 h using an E/T ratio of 5:1 . 2d of pretreatment was optimal for
enhancing ADCC. rIL-4 was inactive and IL-4-depleted Con A-induced spleen
lymphokine retained its ADCC-stimulating activity. Antibody to IFN-7 blocked
the ADCC-promoting effect of the lymphokine, suggesting a major role for this
factor.
We thank C. Taforo and the Cetus Assay Lab for murine IFN-,B, and for IFN and IL-2
assays; T. Mossman for IL-4 titering of lymphokine; I. Braude for help with immunoaf-
finity columns; M. Doyle for the rabbit anti-IL-2 antiserum; and Ruth Bengelsdorf and
Kathy Levenson for manuscript preparation.
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